Literature DB >> 15320850

Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction.

M A Khan1, C S Thompson, M R Dashwood, F H Mumtaz, R J Morgan, D P Mikhailidis.   

Abstract

Bladder outlet obstruction (BOO) is a common disorder that is associated with urinary tract symptoms. Nitric oxide (NO), synthesized by NO synthase (NOS) is a potent vasodilator that is present throughout the urinary tract and the corpus cavernosum. Endothelin-1 (ET-1) conversely is a potent vasoconstrictor peptide that is similarly distributed throughout the urinary tract. ET-1 and NO as well as possessing opposing actions regulate each other's synthesis. The disruption of the balance between ET-1 and NO is associated with various vascular pathologies. However, their potential roles in the pathogenesis of urinary tract disorders, secondary to BOO, is not well established. New Zealand White rabbits with BOO are considered to be a suitable model of the human condition. Hence, using this model, we systematically investigated the potential roles of ET-1 and NO in the pathogenesis of the various urological disorders associated with BOO. In this review we discuss the results of our studies, which support the concept that an imbalance between ET-1 and NO may be associated with the pathogenesis of urinary tract disorders secondary to BOO. We also discuss the potential clinical implications of this association. This review is based on the Bard Silver Medal Lecture given (by MAK) at the 2002 British Association of Urological Surgeons (BAUS) annual meeting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15320850     DOI: 10.2174/1570161033386600

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  6 in total

1.  Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.

Authors:  Steven A Kaplan; Ricardo R Gonzalez
Journal:  Rev Urol       Date:  2007

Review 2.  Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.

Authors:  Emilio Sacco; Francesco Pinto; Pierfrancesco Bassi
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-15

3.  Inhibition of vascular smooth muscle inward-rectifier K+ channels restores myogenic tone in mouse urinary bladder arterioles.

Authors:  Nathan R Tykocki; Adrian D Bonev; Thomas A Longden; Thomas J Heppner; Mark T Nelson
Journal:  Am J Physiol Renal Physiol       Date:  2017-02-01

Review 4.  Excitability and contractility in arterioles and venules from the urinary bladder.

Authors:  Nathan R Tykocki; Frederick C Monson
Journal:  Curr Top Membr       Date:  2020-02-17       Impact factor: 3.049

5.  Effect of ethanol on the response of the rat urinary bladder to in vitro ischemia: protective effect of alpha-lipoic acid.

Authors:  Robert M Levin; Mark Danek; Catherine Whitbeck; Niels Haugaard
Journal:  Mol Cell Biochem       Date:  2005-03       Impact factor: 3.396

6.  Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.

Authors:  Dean S Elterman; Bilal Chughtai; Richard K Lee; Alexis E Te; Steven A Kaplan
Journal:  Rev Urol       Date:  2012
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.